ReviewImmunological reviews2021
Novel mechanisms and clinical trial endpoints in intestinal fibrosis.
Review in Immunological reviews, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06945549 (Evaluation of Intestinal Lesions and Disease Activity in Inflammatory Bowel Disease Based on 18F-FAPI PET Imaging), which is not on this map. Cited by 75 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of Intestinal Lesions and Disease Activity in Inflammatory Bowel Disease Based on 18F-FAPI PET Imaging
Who cites it
75 citing papers in PubMed, 107 citations in OpenAlex.
- ALG10 Alleviates IBD-Related Intestinal Fibrosis by Modulating the TGF-β1/PI3K/Akt Signaling Pathway.Digestive diseases and sciences · 2026Article
- Comparison of the efficacy of TXNDC5 monoclonal antibody versus conventional drugs in the treatment of intestinal fibrosis associated with inflammatory bowel disease.Journal of molecular histology · 2026Article
- Calcineurin Inhibitor-Based Triple Immunosuppressive Therapy Induces Profibrotic Changes in the Jejunal Mucosa of Male Rats: A Digital Image Analysis of Collagen Fibers.Biomedicines · 2026Article
- Oral hydrogel systems in lower gastrointestinal disorders: From disease-based therapy to microbiota-guided design.Materials today. Bio · 2026Review
- Comparison of [Molecular imaging and biology · 2026Article
- Analysis of Periostin, TGF-β, and SLUG Expression in Inflammatory Bowel Disease in Pediatric Patients and Their Clinical Implications.Journal of clinical medicine · 2026Article
- Small Interfering RNA (siRNA) as a Targeted Therapy for Acute Respiratory Distress Syndrome: Evidence from Experimental Models.International journal of molecular sciences · 2026Review
- Bone Marrow Mesenchymal Stem Cell Hydrogel-Mediated Fibroblast Reprogramming Restores Intestinal Function in Adhesive Small Bowel Obstruction.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Myofibroblast-Driven Crohn's Disease Fiber Stricture Fibrotic Microenvironment: High-Resolution Spatial Transcriptomic Analysis.Cellular and molecular gastroenterology and hepatology · 2026Article
- Dual-source DPP4 drives intestinal fibrosis in Crohn's disease: synergistic therapeutic targeting of host and microbiota pathways.Gut microbes · 2025Article
- TMAO and the gut microbiome: implications for the CVD-CKD-IBD axis.Annals of medicine · 2025Review
- Four-class classification of tumor-induced colorectal obstruction histopathology: A ResNet-mamba-mased study on cellular interaction pattern recognition.Scientific reports · 2025Article
- Quantitative MRI radiomics approach for evaluating muscular alteration in Crohn disease: development of a machine learning-nomogram composite diagnostic tool.Abdominal radiology (New York) · 2025Article
- Elucidating the role of IgA plasma cells and PECAM1-CD38 interaction in intestinal fibrosis: a single-cell RNA sequencing analysis in Crohn's disease.BMC gastroenterology · 2025Article
- The Interleukin-8-CXCR1/2 Axis as a Therapeutic Target in Peritoneal Carcinomatosis.Current oncology (Toronto, Ont.) · 2025Review
- CT-based delta-radiomics signature of visceral adipose tissue for prediction of disease progression in ileal stricturing Crohn's disease.Japanese journal of radiology · 2025Article
- Fibrosis: cross-organ biology and pathways to development of innovative drugs.Nature reviews. Drug discovery · 2025Review
- Molecular Basis of Chronic Intestinal Wall Fibrosis in Inflammatory Bowel Diseases.International journal of molecular sciences · 2025Review
- Restoring Prostacyclin/PGI2-PTGIR signaling alleviates intestinal fibrosis in Crohn's disease via fibroblast-specific YAP/TAZ inhibition.Journal of Crohn's & colitis · 2025Article
- Prediction of endoscopic restenosis after endoscopic balloon dilation in patients with Crohn's disease: a machine learning approach.Surgical endoscopy · 2025Article
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 2 countries.
Funding
Abstract
The incidence of inflammatory bowel diseases (IBD) worldwide has resulted in a global public health challenge. Intestinal fibrosis leading to stricture formation and bowel obstruction is a frequent complication in Crohn's disease (CD), and the lack of anti-fibrotic therapies makes elucidation of fibrosis mechanisms a priority. Progress has shown that mesenchymal cells, cytokines, microbial products, and mesenteric adipocytes are jointly implicated in the pathogenesis of intestinal fibrosis. This recent information puts prevention or reversal of intestinal strictures within reach through innovative therapies validated by reliable clinical trial endpoints. Here, we review the role of immune and non-immune components of the pathogenesis of intestinal fibrosis, including new cell clusters, cytokine networks, host-microbiome interactions, creeping fat, and their translation for endpoint development in anti-fibrotic clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.